Alemtuzumab

Chronic Myeloid Leukemia

Diane Georgemonoclonal_antibodyPhase 2/3Active

BB

71/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 59/ 100
Competitive Position: 95/ 100

Competitive context

77 Active assets in the Chronic Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Nilotinib Novartis Pharmaceuticals	Phase 4	BBB
Cyclophosphamide City of Hope Medical Center	Phase 3	BBB
Sargramostim Virginia Commonwealth University	Phase 2	BBB
Methotrexate M.D. Anderson Cancer Center	Phase 3	BBB
Therapeutic Allogeneic Lymphocytes University of Chicago	Phase 2	BBB

View all 50 →

Same molecule, other indications

Alemtuzumab is also rated in:

relapsing-remitting multiple sclerosisActive

BBB

Indicative · Phase 4

73 / 100

myelodysplastic/myeloproliferative neoplasmDormant

BB

Indicative · Phase 2

71 / 100

B-cell chronic lymphocytic leukemiaDormant

BB

Indicative · Phase 3

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.